<?xml version="1.0" encoding="UTF-8"?>
<abstract abstract-type="author-highlights" id="ab005">
 <title>Highlights</title>
 <p>
  <list list-type="simple" id="l0020">
   <list-item id="o0035">
    <label>•</label>
    <p id="p0035">WHO published draft Target Product Profiles (TPPs) for Rift Valley Fever virus (RVFV) vaccines.</p>
   </list-item>
   <list-item id="o0040">
    <label>•</label>
    <p id="p0040">The TPPs contain restrictive requirements aimed at reducing the risk of genetic reassortment.</p>
   </list-item>
   <list-item id="o0045">
    <label>•</label>
    <p id="p0045">We find no evidence for reassortment despite use of live RVFV vaccines.</p>
   </list-item>
   <list-item id="o0050">
    <label>•</label>
    <p id="p0050">If genetic reassortment occurred with wild-type RVFV it would be of no consequence.</p>
   </list-item>
   <list-item id="ce.list-item_msh_r5p_jlb">
    <p id="ce.para_vjc_r5p_jlb">The hypothetical risks of reassortment do not outweigh the benefits of vaccination</p>
   </list-item>
  </list>
 </p>
</abstract>
